000 03681nam a22005655i 4500
001 978-84-938062-7-9
003 DE-He213
005 20210420092429.0
007 cr nn 008mamaa
008 121026s2011 sp | s |||| 0|eng d
020 _a9788493806279
_9978-84-938062-7-9
024 7 _a10.1007/978-84-938062-7-9
_2doi
050 4 _aRA427.8
072 7 _aMBN
_2bicssc
072 7 _aMED076000
_2bisacsh
072 7 _aMBN
_2thema
082 0 4 _a613
082 0 4 _a614.44
245 1 0 _aIncentives for Research, Development, and Innovation in Pharmaceuticals
_h[electronic resource] /
_cedited by Walter A. Garcia-Fontes.
250 _a1st ed. 2011.
264 1 _aMadrid :
_bSpringer Healthcare Iberica :
_bImprint: Springer Healthcare,
_c2011.
300 _aIX, 96 p.
_bonline resource.
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
347 _atext file
_bPDF
_2rda
490 1 _aSeries economia de la salud y gestion sanitaria
505 0 _aIntroduction -- Incentives for innovation: a survey -- Incentives for innovation: neglected diseases -- When patents are not enough: supplementary incentives for pharmaceutical innovation -- The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982 2003 -- The use of pay for performance for drugs: can it improve incentives for innovation? -- Drug Price Regulation: Recent Trends and Downstream Neglected Issues.
520 _aIncentives for innovation are particularly relevant in the pharmaceutical industry where not all social needs provide equally profitable opportunities and where most OECD countries try to implement diffe - rent measures that promote research in these less profitable areas. The lack of incentives for innovation is especially dramatic when we take into account diseases affecting mostly low-income countries, and also diseases affecting small groups of patients. How can incentives be provided to deal with these less profitable acti - vities when no clear markets exist for the innovations being introduced? Some of the contributions of this book go into discussing alternative mechanisms to substitute for these inexistent markets, and situations where traditional instruments such as public procurement or direct subsidies have proven totally insufficient. Also, this book discusses the clear mismatch between the size of the markets being targeted and the incentives being provided.
650 0 _aHealth promotion.
650 0 _aHealth economics.
650 0 _aHealth informatics.
650 0 _aMedicine.
650 1 4 _aHealth Promotion and Disease Prevention.
_0https://scigraph.springernature.com/ontologies/product-market-codes/H27010
650 2 4 _aHealth Economics.
_0https://scigraph.springernature.com/ontologies/product-market-codes/W35000
650 2 4 _aHealth Informatics.
_0https://scigraph.springernature.com/ontologies/product-market-codes/H28009
650 2 4 _aMedicine/Public Health, general.
_0https://scigraph.springernature.com/ontologies/product-market-codes/H00007
700 1 _aGarcia-Fontes, Walter A.
_eeditor.
_4edt
_4http://id.loc.gov/vocabulary/relators/edt
710 2 _aSpringerLink (Online service)
773 0 _tSpringer Nature eBook
776 0 8 _iPrinted edition:
_z9788493806286
776 0 8 _iPrinted edition:
_z9788493806217
830 0 _aSeries economia de la salud y gestion sanitaria
856 4 0 _uhttps://s443-doi-org.br.lsproxy.net/10.1007/978-84-938062-7-9
912 _aZDB-2-SME
912 _aZDB-2-SXM
942 _2ddc
_cEBK
999 _c376288
_d334850